Article Sidebar
Main Article Content
Abstract
Introduction: Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease with variable treatment responses. Identification of molecular biomarkers could personalize treatment and improve outcomes.
Methods: A retrospective cohort study was conducted at a tertiary hospital in Singapore. Patients with HNSCC treated between 2018-2023 were included. Pretreatment tumor biopsies were analyzed for biomarker expression (PD-L1, EGFR, TP53, HPV status) using immunohistochemistry and PCR. Clinical data were collected from medical records. Treatment response, survival, and associations with biomarkers were analyzed.
Results: 250 patients were included. PD-L1 expression was associated with improved response to immunotherapy (p = 0.02). EGFR overexpression correlated with worse overall survival (p = 0.01). TP53 mutations were linked to increased locoregional recurrence (p = 0.03). HPV-positive tumors had a better prognosis (p < 0.001).
Conclusion: Molecular biomarkers show promise in predicting treatment response and survival in HNSCC. Integration of these markers into clinical practice could facilitate personalized treatment strategies.
Keywords
Article Details
Sriwijaya Journal of Otorhinolaryngology (SJORL) allow the author(s) to hold the copyright without restrictions and allow the author(s) to retain publishing rights without restrictions, also the owner of the commercial rights to the article is the author.